Brokers Set Expectations for Edwards Lifesciences Co.’s Q1 2025 Earnings (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Edwards Lifesciences in a note issued to investors on Wednesday, April 17th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will earn $0.74 per share for the quarter, down from their previous estimate of $0.75. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.76 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.78 EPS, Q3 2025 earnings at $0.79 EPS and Q4 2025 earnings at $0.80 EPS.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business’s revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm posted $0.64 EPS.

EW has been the topic of several other research reports. Oppenheimer lifted their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Stifel Nicolaus increased their price objective on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research report on Wednesday, February 7th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Evercore ISI upped their price objective on Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Finally, StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $91.73.

Edwards Lifesciences Stock Performance

EW stock opened at $86.45 on Thursday. The stock has a market capitalization of $52.04 billion, a PE ratio of 37.59, a price-to-earnings-growth ratio of 4.46 and a beta of 1.05. Edwards Lifesciences has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. The company has a 50 day moving average price of $90.14 and a 200 day moving average price of $78.19.

Insiders Place Their Bets

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the stock. Nordea Investment Management AB grew its position in shares of Edwards Lifesciences by 1,224.1% in the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after purchasing an additional 1,488,791 shares in the last quarter. Arlington Trust Co LLC boosted its holdings in shares of Edwards Lifesciences by 5,092.4% in the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after purchasing an additional 12,069 shares in the last quarter. Versor Investments LP grew its position in Edwards Lifesciences by 83.3% during the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock valued at $311,000 after acquiring an additional 2,043 shares during the last quarter. HealthInvest Partners AB purchased a new stake in Edwards Lifesciences during the 4th quarter valued at about $1,587,000. Finally, Telos Capital Management Inc. grew its holdings in Edwards Lifesciences by 158.2% in the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after acquiring an additional 56,000 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.